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Abstract                                    
Chronic lymphocytic leukemia (CLL) is a malignant disorder of B cell origin, with low incidence 
in Asian populations. In this study we investigated the HLA-class I A and B allele frequencies in 
87 Iranian CLL patients and 64 healthy controls using sequence specific primer-polymerase chain 
reaction (SSP-PCR) technique. Our results showed increased frequencies of HLA-A11:01 
(p=0.02) and HLA-B35:01 (p=0.002) alleles and HLA-A11:01/B35:01 haplotype (p=0.036) and 
decreased frequencies of HLA-A01:01 (p=0.02), HLA-A26:01 (p=0.03), HLA-B65:01 (p=0.03) 
and HLA-B53:01 (p<0.00001) alleles in CLL patients compared to the control group. 
Classification of the patients into non-progressive and progressive groups did not reveal 
significant differences for the frequency of any of the HLA-A and B alleles or haplotypes 
between these two subtypes. Comparison between patients with immunoglobulin heavy chain 
variable region genes (IGHV) mutated (n=56) and unmutated (n=31) subtypes showed a 
significant increase in HLA-A32:01 (p=0.05) and HLA-A33:01 (p=0.05) alleles in IGHV 
unmutated patients compared to IGHV mutated patients. Similarly, a higher frequency of HLA-
B52:01 (p=0.037) alleles was observed in CD38+ compared with CD38- patients. Our results 
obtained from an Iranian population indicate that CLL is associated with distinct HLA class I 
alleles and haplotypes some of which are linked to disease prognostic factors. 
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Introduction 
Chronic lymphocytic leukemia (CLL), a hematologic malignancy of CD5
+
 CD19
+
CD23
+
 B-cells 
[1], is considered as the most abundant leukemia in the West [2, 3]. Compared to the Western 
populations, its frequency is low in Asia and Iran [4-6]. Clinically, the disease could either be 
progressive or non-progressive with overall survival time ranging from less than 5 years to more 
than 30 years. Despite recent identification of several prognostic factors [7, 8] the etiology of 
CLL remains obscure. Recent investigations on the immunoglobulin heavy chain variable region 
(IGHV) genes stereotypes of the leukemic B cells suggest involvement of antigen selection in 
initiation or progression of CLL [9, 10]. Sequencing of the expressed IGHV genes has shown that 
patients with CLL can be classified into IGHV mutated or unmutated subtypes [11]. Patients 
having leukemic cells with unmutated IGHV genes usually display a more aggressive disease 
compared to those with mutated IGHV genes [12, 13].  
 
HLA genes are the most polymorphic genes which are involved in antigen presentation to T 
lymphocytes. Expression of certain HLA class I or II alleles has been shown to be associated with 
a variety of infections and autoimmune or malignant disorders [14-16].  
 
Taking into consideration the genetic diversity and variability of HLA alleles in different ethnic 
populations, different HLA class I and II alleles might be associated to a given disease in 
different populations.  
Association of certain HLA class I [17] or HLA class II [14, 18] alleles with the clinical course of 
the disease has also been reported in different malignancies.  
Apart of a few studies [4, 16, 19-26] in which the frequency of HLA alleles has been determined 
in CLL patients from some ethnic populations, association of HLA alleles and CLL prognosis has 
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not been well studied, especially in the Asian CLL patients. In a prior study we reported the 
frequency of some HLA class I A, B and C antigens in a limited number of CLL patients using 
the serological microlymphocytotoxicity technique [4]. Later, we reported the HLA class II allele 
frequencies in a large number of Iranian CLL patients and their correlation to disease progression 
and IGHV mutation [14]. In the current study, we investigated the frequency of HLA-class I A 
and B alleles and haplotypes by SSP-PCR technique in the same set of patients. Contrary to our 
previous serologic HLA class I study, the patients were classified into different molecular and 
clinical subtypes (progressive and non-progressive, IGHV mutated and unmutated, as well as 
CD38+ and CD38- subtypes) which allowed analysis of the association of HLA alleles and 
haplotypes with disease progression.   
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Materials and Methods 
Patients and controls 
In the present study, from 87 Iranian CLL patients, 20 ml of heparinized peripheral blood was 
collected. All patients attended the Hematology and Oncology Clinics of Vail-Asr and Firozgar 
Hospitals, affiliated to Tehran University of Medical Sciences. Consent letter was taken from all 
patients and the study was approved by the Ethical Committee of Tehran University of Medical 
Sciences. CLL diagnosis and classification of our patients have been described previously [14]. 
Patients were considered to have progressive disease if the following criteria were met: 
progression during the preceding 3 months in disease-related anemia (hemoglobin <100 g/l), 
thrombocytopenia (<100 x 109/l) and/or an increase in spleen/liver/lymph node size and/or more 
than a 2-fold increase in the blood lymphocyte count [14, 27, 28]. HLA typing results were 
compared with those obtained from 64 Iranian healthy blood donors. Since the age of the subjects 
does not seem to influence HLA frequency profile, the control group was not age matched with 
CLL patients and was selected from adult volunteers (23-45 years old; mean age: 34 years). 
 
Typing of HLA-A and HLA-B alleles 
HLA class I alleles of patients and controls were defined using low-resolution kits supplied by 
Qiagen Vertriebs GmbH (Vienna, Austria), based on the manufacturer's instructions.  
To define the HLA-A and -B alleles in patients and controls, genomic DNA of each sample was 
amplified by 24 and 48 cycles of PCR reactions for HLA-A and HLA-B specificities, 
respectively. Allele frequencies in CLL patients and controls were calculated by direct counting. 
Two-locus haplotype (HLA-A/B) frequencies in patients and healthy controls were estimated by 
maximum-likelihood method according to the expectation-maximization algorithm using 
Arlequin 2.0 [29].  
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Analysis of IGHV genes mutations  
Total cellular RNA was isolated from PBMCs of CLL patients using RNA-Bee (BioSite, Taby, 
Sweden) based on the guanidine thiocyanate phenol chloroform extraction method. First strand 
cDNA was synthesized from 1–3 ug of total RNA as described previously [14]. To determine the 
IGHV family gene expression by polymerase chain reaction (PCR), serial dilutions of DNA and 
cDNA (1:10 to 1:2000) were prepared and PCR amplification was performed using IGHV 
family-specific degenerative primers. PCR reactions were performed as described [14]. Finally 
clonal PCR products were purified by excision using the QIAquick gel extraction kit (Qiagen, 
Hilden, Germany) and were cloned into pGEM-T easy vector (Promega, Southampton, United 
Kingdom). Sequencing was performed from both directions using the BigDye Terminator Cycle 
Sequencing Reaction Kit (Applied Biosystems, Foster City, CA, USA), and T7 and SP6 primers.  
For each sample IGHV gene was identified by matching to the closest known human germline 
gene using the ImMuno-Gene Tics (IMGT) Database (http://imgt.cines.fr) and the IgBLast search 
(http://www.ncbi.nlm.nih.gov/igblast/). Classification of patients into mutated (n = 56) and 
unmutated (n = 31) subtypes was based on more than 98% homology in nucleotide sequence of 
IGHV genes of the leukemic cells [30].  
 
Statistical analysis 
The association of CLL with HLA-I alleles was analyzed by comparing HLA-A and -B alleles 
frequencies in CLL patients with 64 healthy Iranian controls. Maximum likelihood method was 
used to evaluate the haplotype frequencies for the two-loci. Chi-Square test for 2×2 tables after 
Yates correction was used to define the differences between allele frequencies in patients and 
controls and patients subgroups, using Epi-Info and SPSS statistical packages (SPSS Inc., 
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Chicago, IL). The odds ratios (OR) with 95% confidence intervals (CI) were calculated and p-
values lower than 0.05 were considered to be significant. The Mann–Whitney U test was also 
used to compare the time to first treatment (TTFT), progression free survival (PFS) and overall 
survival (OS) between different CLL subtypes. 
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Results 
HLA-A and B frequencies in CLL patients and controls 
In the current study, 87 CLL patients and 64 healthy donors were included. The frequencies of 
HLA-A and HLA-B alleles in all patients and controls are presented in Tables 1 and 2. Our 
results showed that HLA-A02 and HLA-A24 have the highest frequency among HLA-A alleles 
in CLL patients (25.3% and 16.7%) and controls (15.6% and 16.4%), respectively. HLA-A03 and 
HLA-A11 are the next alleles with higher frequencies in CLL patients. Comparing the frequency 
of HLA-A alleles between patients and controls shows substantially higher frequencies of HLA-
A11 (OR=3.38, p=0.02) and HLA-A02 (OR=1.83, p=0.059) and lower frequencies of HLA-A01 
(OR=0.34, p=0.02) and HLA-A26 (OR=0.32, 0.03) in CLL patients (Table 1). The most 
abundant HLA-B allele in patients was HLA-B35 .This alleles was expressed in CLL patients at a 
significantly higher frequency compared to controls (19% vs. 6.3%, OR=3.51, p=0.002). On the 
other hand  HLA-B53 allele was among the least expressed HLA-B alleles in CLL patients, but 
the most frequent allele expressed in the control subjects (OR=0.04, p=0.00001). HLA-B65:01 
was also observed at significantly lower frequency in patients compared to controls (OR=0.17, 
p=0.03) (Table 2). 
 
Frequencies of HLA-I alleles in CLL subtypes 
The association of HLA-A and HLA-B alleles to disease progression was analyzed in CLL 
patients. The frequencies of HLA-A02:01, HLA-A24:01 and HLA-A03:0 alleles were lower in 
progressive CLL patients, but the differences were not statistically significant. Comparison of 
HLA-A allele frequencies between IGHV mutated and unmutated CLL patients showed a higher 
frequency of HLA-A32:01 (6.5% vs. 0.9%, OR=0.13, p=0.05) and HLA-A33:01 (6.5% vs. 0.9%, 
OR=0.13, p=0.05) in IGHV unmutated compared to IGHV mutated patients. Comparison of 
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CD38
+
 and CD38
-
 groups of patients demonstrated a positive association of HLA-A30:01 and 
HLA-A68:01 alleles with CD38 expression (OR=3.5, p=0.09 and OR=7.9, p=0.06 respectively), 
but the differences were not statistically significant.  
The frequencies of HLA-B alleles were analysed in CLL subtypes. Significant differences were 
observed neither between non-progressive and progressive nor IGHV mutated and unmutated 
CLL subgroups. A significantly higher frequency of HLA-B52:01 was observed in CD38
+
 
compared to CD38
-
 CLL patients (10.4% vs. 2.4%, OR=4.77, p=0.037). The most frequent 
homozygote alleles of HLA-A and HLA-B were HLA-A24:01 (8.5%) and HLA-B35:01 (6.9%) 
in CLL patients (Table 3). None of the controls expressed HLA-B35:01 homozygote allele, but 
the difference between CLL patients and healthy controls was not statistically significant. 
 
HLA-A and -B haplotypes frequency 
The frequencies of two loci haplotypes in CLL patients and healthy controls are shown in Table 
4. HLA-A02:01/B35:01, HLA-A24:01/B35:01, HLA-A03:01/B35:01 and HLA-A11:01/B35:01 
were the most frequent haplotypes in patients, however, only the frequency of the latter  
haplotype was significantly higher in the patients compared to the control group (p=0.036). None 
of the haplotypes was found to be associated to a particular subtype of CLL patients.  
 
Association between TTFT, PFS and OS with HLA I alleles 
Comparison of TTFT, PFS and OS in our CLL patients showed no significant correlations 
between these parameters and frequency of certain HLA-A or -B alleles. 
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Discussion 
Association between HLA antigens and disease initiation or progression has been investigated in 
a limited number of hematological malignancies, including CLL [14]. The frequency of HLA 
class I alleles in CLL has been reported in a few ethnic populations (Table 5). Patients with CLL 
are classified into IGHV mutated and unmutated subtypes based on the mutational status of the 
IGHV genes of the leukemic B-cells [11]. These two different subtypes of patients have different 
molecular and clinical features, in terms of CD38 and ZAP-70 expression and disease 
progression [31, 32]. CLL patients with mutated IGHV genes tend to express lower levels of 
CD38 and ZAP-70 molecules with a milder disease, as compared to patients with  unmutated 
IGHV genes [12, 13, 30].  
 
In the current study, we demonstrated the HLA class I A and B alleles frequencies in a group of 
Iranian CLL patients and healthy controls trying to identify the disease predisposing or protective 
alleles and haplotypes in our patients. Of the HLA-A alleles, HLA-A11:01 was represented at a 
higher frequency in our patients compared with controls (OR=3.38, p=0.02), while the 
frequencies of HLA-A01:01 and HLA-A26:01 alleles were significantly higher in the control 
group (OR=0.34 and 0.32, p=0.02 and 0.03, respectively). Our results are not compatible with 
those of Linet et al who reported no difference in the frequencies of HLA-A01 and HLA-A26 
alleles between their CLL patients and healthy controls [21], which may partly be due to ethnic 
differences.  
 
Among the HLA-B alleles we observed a significantly higher frequency of HLA-B35:01 allele in 
our CLL patients compared to controls (OR=3.51, p=0.002), showing a strong association of this 
allele with CLL disease.  A similar finding was also reported by others [20], though controversial 
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results have also been published [16, 21, 22, 25, 33]. An increased frequency of the HLA-B35 
allele has also been reported in some other malignancies and autoimmune diseases from different 
ethnic populations, including Hodgkin's lymphoma [34], autoimmune thyroiditis [35], 
autoimmune hepatitis [36] autoimmune arthritis [37], Moyamoya [38], and pemphigus vulgaris 
[39], suggesting a critical correlation of this allele with hematologic malignancies and other 
pathologic conditions. 
In contrast to higher frequency of HLA-B35:01 in CLL patients, a significantly lower frequency 
of HLA-B65:01 (OR=0.17, p=0.03) and particularly HLA-B53:01 (OR=0.04, p=0.00001) alleles 
was observed in our patients compared to the healthy controls, suggesting a protective role for 
these alleles. To our knowledge negative association of these two alleles with CLL has not been 
reported in other ethnic populations, suggesting ethnical influence of HLA association to CLL 
disease.  
The differences observed in allele frequencies between patients and controls might be interpreted 
to reflect differences between different subgroups of the Iranian population. Ethnically, the 
Iranian population is derived from the Caucasian ancestral, though it is composed of different 
ethnic subpopulations, including Turk, Kurd, Arab, Fars, Balooch, Lor and Turkman people [40]. 
These populations are living in different provinces of Iran. However, Tehran, the capital of Iran, 
is populated with all these subgroups. Thus, since the samples were collected from patients and 
personnel of two university hospitals located in Tehran, we assume that it is unlikely that the 
differences observed in allele frequencies between our patients and controls are associated to 
population subgroups. 
Comparison of the frequency of HLA-A alleles in different subtypes of our CLL patients showed 
a significantly higher frequency of HLA-A32:01 and HLA-A33:01 alleles in IGHV unmutated 
compared to mutated patients.  
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A higher frequency of HLA-A33 allele has previously been reported in patients with other 
disorders [41, 42]. Among the HLA-B alleles, HLA-B52:01 allele was expressed at a higher 
frequency in CLL patients expressing CD38 molecule, compared to CD38
-
 patients (OR=4.77, 
p=0.037). Association between expression of CD38 and/or lack of IGHV mutation with disease 
progression has been reported in various studies [7, 43, 44]. Accordingly, HLA-A32:01, A33:01 
and B52:01 alleles seem to be positively associated to disease progression in our CLL patients. 
As we reported previously [14], non-progressive and IGHV mutated CLL patients had a higher 
PFS (44 and 37 months, respectively) compared to progressive and unmutated (13 and 9 month, 
respectively) CLL patients (p=0.006 and 0.001, respectively). Also, IGHV unmutated CLL 
patients had significantly lower overall survival compared to mutated patients (98% vs. 84%, 
p=0.04). Our findings of lack of significant correlations between TTFT, PFS and OS with 
frequency of expression of none of the HLA-A or –B alleles in our CLL patients suggest that 
different prognostic parameters may give different levels of associations with HLA alleles 
frequency.  
 
The negative association of certain HLA-I antigens such as HLA-B53:01 with CLL implies 
expansion of a repertoire of tumor-specific CTL clones which enables effective 
immunomonitoring and control of tumor cells in healthy subjects. The association of some HLA 
alleles or haplotypes with CLL disease and its progression may also confer a protective role in 
CLL in which the leukemic cells and/or antigen presenting cells can efficiently present tumor 
related antigens to autologous T cells, leading to their stimulation. Differential frequency of some 
HLA class I alleles in different subtypes of our CLL patients is in agreement with this 
proposition.  
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Altogether, our findings together with the signaling effects of HLA-I molecules and effects on 
tumor cells behavior imply that certain HLA antigens may influence the immune response to 
leukemic CLL cells, probably through different mechanisms such as presentation of a tumor-
associated antigen by leukemic B cells or by professional antigen-presenting cells to autologous 
T cells and shaping the repertoire of T cells as explained. Alternatively, such alleles may be 
regarded as markers for other pathogenic genes remaining in linkage disequilibrium with these 
loci.  
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Table 1: HLA-A allele frequencies among Iranian CLL patients and healthy 
controls. 
 
Alleles 
CLL (n=87)              
(174 alleles) 
Healthy controls (n=64) 
(128 alleles) 
Odds Ratio (95% CI) P value 
A02:01
 
 44  (25.3)  a 20 (15.6) 1.83 (0.98-3.43) 0.059 
A24:01 29 (16.7) 21 (16.4) 1.02 (0.53-1.97) 0.92 
A03:01 26 (14.9) 18 (14.1) 1.07 (0.54-2.16) 0.96 
A11:01 21 (12.1) 5 (3.9) 3.38 (1.16-10.55) 0.02 
A01:01 8 (4.6) 16 (12.5) 0.34 (0.13-0.87) 0.02 
A32:01 8 (4.6) 7 (5.5) 0.83 (0.27-2.63) 0.93 
A29:01 7 (4) 3 (2.3) 1.75 (0.45-6.51) 0.63 
A30:01 7 (4) 5 (3.9) 1.03 (0.33-3.17) 0.8 
A26:01 6 (3. 4) 13 (10.2) 0.32 (0.1-0.92) 0.03 
A33:01 5 (2.9) 8 (6.3) 0.44 (0.12-1.54) 0.25 
A68:01 4 (2.3) 6 (4.7) 0.48 (0.11-1.96) 0.41 
A23:01 2 (1.1) 5 (3.9) 0.29 (0.04-1.69) 0.23 
A31:01 2 (1.1) 0 1.12  0.61 
A66:01 2 (1.1) 0 1.12 0.61 
A34:01 1 (0.6) 0  NI 0.87 
A69:01 1 (1.1) 0  NI  0.87 
A74:01 1 (1.1) 0  NI  0.87 
A64:01 0  1 (0.8) 0 0.87 
a
 The results represent the number (%) of the specified alleles expressed in the study groups, NI= not 
identified, 
 
CI = confidence interval (lower limit–upper limit). 
 
  
2 
 
Table 2: HLA-B allele frequencies among Iranian CLL patients and healthy 
controls. 
 
Alleles 
CLL (n=87)              
(174 alleles) 
Healthy controls (n=64) 
(128 alleles) 
Odds Ratio (95% CI) P value 
B35:01 33 (19)  a 8 (6.3) 3.51 (1.48-8.6) 0.002 
B51:01 17 (9.8) 14 (10.9) 0.88 (0.39-1.98) 0.88 
B07:01 10 (5.7) 10 (7.8) 0.72 (0.27-1.94) 0.63 
B13:01 9 (5.2) 7 (5.5) 0.94 (0.31-2.9) 0.88 
B52:01 8 (4.6) 2 (1.6) 3.04 (0.58-21.07) 0.19 
B18:01 7 (4) 1 (0.8) 5.15 (0.64-41.34) 0.14 
B38:01 7 (4) 10 (7.8) 0.49 (0.16-1.46) 0.23 
B08:01 6 (3.4) 7 (5.5) 0.62 (0.18-2.11) 0.57 
B41:01 5 (2.9) 7 (5.5) 0.51 (0.14-1.58) 0.4 
B62:01 5 (2.9) 2 (1.6) 1.86 (0.36-9.33) 0.71 
B44:01 4 (2.3) 4 (3.1) 0.73 (0.15-3.54) 0.94 
B50:01 4 (2.3) 2 (1.6) 1.48 (0.27-7.91) 0.97 
B55:01 4 (2.3) 9 (7) 0.31 (0.08-1.14) 0.08 
B27:01 3 (1.7) 1 (0.8) 2.23 (0.23-20.97) 0.84 
B40:01 3 (1.7) 3 (2.3) 0.73 (0.12-4.62) 0.97 
B49:01 2 (1.1) 4 (3.1) 0.36 (0.05-2.33) 0.42 
B58:01 2 (1.1) 1 (0.8) 1.48 (0.13-16.05) 0.79 
B63:01 2 (1.1) 3 (2.3) 0.48 (0.08-2.89) 0.72 
B65:01 2 (1.1) 8 (6.3) 0.17 (0.03-0.91) 0.03 
B15:01 1 (0.6) 0 NI 0.87 
B37:01 1 (0.6) 1 (0.8) 0.73 (0.05-11.65) 0.61 
B45:01 1 (0.6) 2 (1.6) 0.36 (0.03-4.01) 0.79 
B53:01 1 (0.6) 17 (13.3) 0.04 (0.01-0.32) 0.00001 
B57:01 1 (0.6) 3 (2.3) 0.24 (0.03-2.33) 0.2 
B56:01 0 1 (0.8) 0 0.87 
B72:01 0 1 (0.8) 0 0.87 
a
 The results represent the number (%) of the specified alleles expressed in the study groups, 
 
NI= not 
identified, 
 
CI = confidence interval (lower limit–upper limit). 
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Table 3: HLA-A, B homozygote alleles frequency in CLL and controls. 
 
Alleles 
Homozygote alleles 
Odds Ratio 
 (95% CI)  
P value 
CLL 
 (n=87)               
Healthy 
controls (n=64) 
A24:01 5 (8.5)  a 2 (3.1) 1.89  (0.37-9.18) 0.71 
A02:01 3 (3.5) 1 (1.6)   2.22 (0.23-20.5) 0.85 
B35:01 6 (6.9) 0 NI 0.08 
B4005:01 2 (2.3) 0 NI 0.61 
    a
 The results represent the number (%) of the specified alleles expressed in the study groups,  
         
NI= not identified, CI = confidence interval (lower limit–upper limit). 
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Table 4: HLA-A/B haplotype frequency in CLL patients and controls.  
 
 
a
 The results represent the number (%) of the specified alleles expressed in the study groups, 
 
NI= not 
identified, CI = confidence interval (lower limit–upper limit). Data for the most frequent haplotypes are 
presented in the table. 
 
Haplotypes 
HLA-A/B 
haplotype 
frequency in CLL 
patients 
HLA-A/B 
haplotype 
frequency in 
controls 
Odds Ratio (95% CI)  P value 
A02:01/B35:01 10 (5.7) a 3 (2.3) 2.54 (0.69-8.73)  0.25 
A24:01/B35:01 10 (5.7) 2 (1.6) 3.84 (0.82-16.5) 0.12 
A03:01/B35:01 10 (5.7) 2 (1.6) 3.84 (0.82-16.5) 0.12 
A11:01/B35:01 8 (4.6) 0 NI 0.036 
A02:01/B51:01 5 (2.9) 5 (3.9) 0.73 (0.22-2.49) 0.86 
A32:01/B35:01 5 (2.9) 1 (0.8) 3.76 (0.43-31.1) 0.38 
A02:01/B07:01 5 (2.9) 0 NI 0.14 
A03:01/B51:01 4 (2.3) 5 (3.9) 0.58 (0.16-2.15) 0.64 
A26:01/B51:01 4 (2.3) 2 (1.6) 1.48 (0.27-7.91) 0.97 
A03:01/B18:01 4 (2.3) 1 (0.8) 2.99 (0.33-26.02) 0.97 
A02:01/B41:01 3 (1.7) 3 (2.3) 0.73 (0.15-3.59) 0.97 
A02:01/B38:01 3 (1.7) 3 (2.3) 0.73 (0.15-3.59) 0.97 
A02:01/B13:01 3 (1.7) 3 (2.3) 1.11 (0.19-6.51) 0.73 
A02:01/B18:01 3 (1.7) 1 (0.8) 2.23 (0.23-20.97) 0.84 
A26:01/B07:01 3 (1.7) 1 (0.8) 2.23 (0.23-20.97) 0.84 
A24:01/B62:01 3 (1.7) 0  NI 0.36 
A02:01/B52:01 3 (1.7) 0 NI 0.36 
A24:01/B52:01 3 (1.7) 0 NI 0.36 
A24:01/B53:01 2 (1.15) 4 (3.12) 0.36 (0.07-1.98) 0.42 
A24:01/B55:01 2 (1.15) 4 (3.12) 0.36 (0.07-1.98) 0.42 
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Table 5: Comparison of HLA class I alleles frequencies in B-CLL patients from different ethnic populations 
Country 
No. of 
patients 
(controls) 
HLA-I alleles 
Ref. 
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1
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3
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1
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Germany 
101 
(157) * 
24.8 
(31.9) 
59.4 
(48.4) 
NI NI NI NI NI 4  
(11.5) 
NI NI NI NI 17.8 
(21.7) 
NI NI NI NI 9.9 
(18.5) 
NI NI NI NI NI NI NI 16 
UK 
85 
(600) 
34 
(36) 
55 
(48) 
19 
(24) 
19 
(17) 
7 
(9) 
15 
(12) 
NI 
4 
(9) 
NI NI 6 
(7) 
31 
(28) 
33 
(33) 
2 
(3) 
13 
(12) 
0 
(5) 
7 
(8) 
12 
(12) 
8 
(13) 
NI NI NI NI NI NI 33 
USA 
88 
(3761) 
32 
(30) 
56 
(50) 
27 
(30) 
23 
(20) 
8 
(10) 
7 
(10) 
10 
(10) 
NI NI NI 14 
(10) 
24 
(20) 
16 
(20) 
8 
(10) 
14 
(10) 
9 
(10) 
8 
(10) 
19 
(20) 
9 
(10) 
NI NI NI NI NI NI 21 
UK 
57 
(57) 
53 
(30) 
54 
(51) 
16 
(23) 
18 
(16) 
4 
(9) 
9 
(18) 
NI 
7 
(7) 
NI NI 
11 
(16) 
30 
(30) 
44 
(19) 
5 
(5) 
12 
(5) 
7 
(7) 
4 
(7) 
5 
(11) 
11 
(9) 
0 
(2) 
NI NI 
2 
(2) 
NI NI 25 
UK 
83 
(385) 
30.1 
(36.7) 
62.7 
(45.7) 
NI NI 
10.8 
(7.8) 
NI NI NI NI NI NI NI 
21.7 
(26.5) 
NI NI NI NI NI NI NI NI NI NI NI NI 26 
Germany 
79 
(329) 
20.3 
(30.4) 
60.8 
(45.9) 
NI NI NI NI NI NI NI NI NI NI 16.5 
(22.2) 
NI NI 11.4 
(10.3) 
NI 
10.1 
(15.5) 
NI NI NI NI NI NI NI 22 
IRAN 
87 
(64) 
4.6 
(12.5) 
25.3 
(15.6) 
14.9 
(14.1) 
NI NI 12.1 
(3.9) 
4 
(2.3) 
NI 
4 
(3.9) 
2.3 
(4.7) 
NI 
5.7 
(7.8) 
NI 
5.2 
(5.5) 
NI 
4 
(0.8) 
1.7 
(0.8) 
19 
(6.3) 
1.7 
(2.3) 
2.9 
(5.5) 
2.3 
(3.1) 
9.8 
(10.9) 
0.6 
(13.3) 
2.3 
(7) 
1.1 
(0.8) 
Present 
study 
*Data represent the percentage of alleles in CLL (normal controls), NI= not identified 
 
 
